BioPharma Resources

Drug Trial Radar · NCT05800015

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels

Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Actual

Start

Aug 8, 2023

Primary completion

Jan 16, 2030

Study completion Dec 23, 2031

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Apr 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not approved for use outside of this study by any Health Authority. Examples of chemotherapy drugs include the following: Paclitaxel plus carboplatin, and Pemetrexed plus cisplatin. The study is being conducted in patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is for treating advanced NSCLC, in comparison with cemiplimab and chemotherapy. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in your blood at different times * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects) * How administering the study drugs might improve your quality of life

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • fianlimabDrug

    Administered intravenously (IV) every 3 weeks (Q3W)

  • cemiplimabDrug

    Administered IV Q3W

  • PemetrexedDrug

    IV Infusion, Q3W

  • PaclitaxelDrug

    IV Infusion, Q3W

  • CarboplatinDrug

    IV Infusion, Q3W

  • CisplatinDrug

    IV infusion, Q3W

  • PlaceboDrug

    IV infusion, Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) as assessed by blinded independent review committee (BICR) using RECIST 1.1Time frame: Up to 136 Weeks
  2. Overall Survival (OS)Time frame: Up to 5 years

Locations

76 sites in 10 countries. Site status is shown where the registry gives one.

  • Arizona Clinical Research Center

    Tucson, Arizona

  • Yuma Regional Medical Center

    Yuma, Arizona

  • The Oncology Institute of Hope & Innovation

    Cerritos, California

  • Crosson Cancer Institute

    Fullerton, California

  • St. Joseph Hospital Orange

    Orange, California

  • Desert Hematology Oncology Medical Group Incorporated

    Rancho Mirage, California

  • Emad Ibrahim, MD, Inc.

    Redlands, California

  • PIH Health Hospital

    Whittier, California

  • Rocky Mountain Regional VA Medical Center

    Aurora, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Clermont Oncology Center

    Clermont, Florida

  • Miami Veterans Administration HealthCare System

    Miami, Florida

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida

  • Tallahassee Memorial Healthcare

    Tallahassee, Florida

  • University of Illinois

    Chicago, Illinois

  • Northwest Oncology and Hematology

    Rolling Meadows, Illinois

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana

  • Hattiesburg Clinic

    Hattiesburg, Mississippi

  • Capital Health Hopewell Medical Center

    Pennington, New Jersey

  • New Mexico Cancer Care Alliance

    Albuquerque, New Mexico

  • NYU Langone Health Perlmutter Cancer Center

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Clinical Research Alliance Inc

    Westbury, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • Thompson Cancer Survival Center (TCSC ) - Downtown

    Knoxville, Tennessee

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • University of Virginia Medical Center

    Charlottesville, Virginia

  • Bon Secours Cancer Institute Richmond

    Midlothian, Virginia

  • Macquarie University Health Science Center (MQ Health)

    Macquarie Park, New South Wales, Australia

  • Southern Medical Day Care Centre

    Wollongong, New South Wales, Australia

  • Ballarat Regional Integrated Cancer Centre (BRICC)

    Ballarat, Victoria, Australia

  • Bendigo Hospital

    Bendigo, Victoria, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia

  • St John of God Murdoch Hospital

    Murdoch, Western Australia, Australia

  • British Columbia Cancer Center-Kelowna

    Kelowna, British Columbia, Canada

  • Hopital Cite de la Sante

    Laval, Quebec, Canada

  • Israeli Georgian Medical Research Clinic Helsicore

    Tbilisi, Georgia

  • Research Institute of Clinical Medicine

    Tbilisi, Georgia

  • LTD New Hospitals

    Tbilisi, Georgia

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.